Bustamante, Regine Fher S.
HRN: 21-22-80 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/14/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/14/2023
10/21/2023
IV
80mg
Q8hours
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes